ImmunityBio, a biotech company developing novel cancer treatments, has been valued at $30 per share in a coverage initiation report by EF Hutton, an investment bank. Recall that EF Hutton was known as one of the top banks for SPAC deals, including Donald Trump‘s Trump Media & Technology Group. The…